HIGHLIGHTS
- who: Gaurav Kumar Pandey from the Netherlands Cancer Institute, Plesmanlaan, CX Amsterdam, the Netherlands Radboud University have published the article: Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma, in the Journal: (JOURNAL) of February/21,/2023
- what: By subjecting autochthonous mice or xenografts to mevalonate pathway inhibition (zoledronic acid) and PRC2 inhibition (tazemetostat) the authors demonstrate a potent anti-tumor effect suggesting a targeted combination therapy for Exploiting this vulnerability pharmacologically, the authors show that mesothelioma cells lacking BAP1 are more susceptible to the mevalonate pathway inhibitor zoledronic acid (ZA), identifying another Bap1loss . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.